CA2393004A1 - Procede de diagnostic de maladies neurodegeneratives - Google Patents

Procede de diagnostic de maladies neurodegeneratives Download PDF

Info

Publication number
CA2393004A1
CA2393004A1 CA002393004A CA2393004A CA2393004A1 CA 2393004 A1 CA2393004 A1 CA 2393004A1 CA 002393004 A CA002393004 A CA 002393004A CA 2393004 A CA2393004 A CA 2393004A CA 2393004 A1 CA2393004 A1 CA 2393004A1
Authority
CA
Canada
Prior art keywords
alpha
test sample
acetylcholine receptor
nicotinic acetylcholine
receptor protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002393004A
Other languages
English (en)
Inventor
Daniel H. S. Lee
Allen B. Reitz
Carlos R. Plata-Salaman
Hoau-Yan Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2393004A1 publication Critical patent/CA2393004A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/944—Acetylcholine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des procédés pour diagnostiquer une maladie neurodégénérative telle que la maladie d'Alzheimer, surveiller l'évolution de la maladie et pronostiquer cette maladie et/ou surveiller l'efficacité thérapeutique de n'importe quelle intervention ou n'importe quel traitement de la maladie, y compris pour mesurer le taux de la protéine réceptrice d'acétylcholine nicotinique .alpha.7.
CA002393004A 1999-12-01 2000-11-16 Procede de diagnostic de maladies neurodegeneratives Abandoned CA2393004A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16823899P 1999-12-01 1999-12-01
US60/168,238 1999-12-01
PCT/US2000/031467 WO2001040261A1 (fr) 1999-12-01 2000-11-16 Procede de diagnostic de maladies neurodegeneratives

Publications (1)

Publication Number Publication Date
CA2393004A1 true CA2393004A1 (fr) 2001-06-07

Family

ID=22610681

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002393004A Abandoned CA2393004A1 (fr) 1999-12-01 2000-11-16 Procede de diagnostic de maladies neurodegeneratives

Country Status (5)

Country Link
EP (1) EP1233979A1 (fr)
JP (1) JP2003530542A (fr)
AU (1) AU1920401A (fr)
CA (1) CA2393004A1 (fr)
WO (1) WO2001040261A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569354B2 (en) 2008-11-19 2013-10-29 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
US8710227B2 (en) 2010-05-17 2014-04-29 Envivo Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US8884017B2 (en) 2001-12-27 2014-11-11 Bayer Intellectual Property Gmbh 2-heteroarylcarboxylic acid amides
US9585877B2 (en) 2012-05-08 2017-03-07 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003276107A1 (en) * 2003-04-24 2004-11-19 Universitat Zurich Method of monitoring immunotherapy
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
WO2010064250A1 (fr) 2008-12-04 2010-06-10 Yeda Research And Development Co. Ltd. Compositions et procédés pour le diagnostic et le traitement d'un cancer et de maladies neurodégénératives liées à beclin-1
US8436145B2 (en) 2008-12-04 2013-05-07 Yeda Research And Development Co. Ltd. Compositions and methods for diagnosing and treating cancer and neurodegenerative diseases related to Beclin-1
MX2013003344A (es) 2010-09-23 2013-06-28 Abbvie Inc Monohidrato de un derivado de azaadamantano.
EP2872899B1 (fr) * 2012-07-13 2018-07-11 Pain Therapeutics, Inc. Analyse de la maladie d'alzheimer chez un patient vivant
US10282875B2 (en) 2015-12-11 2019-05-07 International Business Machines Corporation Graph-based analysis for bio-signal event sensing
JP2022538955A (ja) 2019-03-19 2022-09-07 ケンブリッジ コグニション リミテッド 精神障害のための治療の診断および推奨の方法および利用
KR102246021B1 (ko) * 2019-10-10 2021-04-29 연세대학교 산학협력단 섬유증의 진단용 조성물 및 이를 이용한 방법

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8884017B2 (en) 2001-12-27 2014-11-11 Bayer Intellectual Property Gmbh 2-heteroarylcarboxylic acid amides
US8569354B2 (en) 2008-11-19 2013-10-29 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
US8642638B2 (en) 2008-11-19 2014-02-04 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
US8815933B2 (en) 2008-11-19 2014-08-26 Forum Pharmaceuticals, Inc. Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
US8710227B2 (en) 2010-05-17 2014-04-29 Envivo Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US9108961B2 (en) 2010-05-17 2015-08-18 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride
US9273044B2 (en) 2010-05-17 2016-03-01 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US9550767B2 (en) 2010-05-17 2017-01-24 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US9585877B2 (en) 2012-05-08 2017-03-07 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function

Also Published As

Publication number Publication date
JP2003530542A (ja) 2003-10-14
WO2001040261A1 (fr) 2001-06-07
EP1233979A1 (fr) 2002-08-28
AU1920401A (en) 2001-06-12

Similar Documents

Publication Publication Date Title
US6447989B1 (en) Kidney disease detection and treatment
US6589748B2 (en) Method for kidney disease detection and treatment
AU2015262399B9 (en) Surrogate biomarker for evaluating intracerebral amyloid beta peptide accumulation and method for analysis thereof
CN106062563B (zh) 用于阿尔兹海默症的早期诊断的生物标志物及方法
US20230243853A1 (en) Method of identifying biomarkers of neurological diseases and diagnosis of neurological diseases
Ghanbari et al. Biochemical assay for AD7C‐NTP in urine as an Alzheimer's disease marker
WO2004001421A2 (fr) Procede de diagnostic et diagnostic differentiel des maladies neurologiques
Marksteiner et al. Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: A pilot-study
CA2393004A1 (fr) Procede de diagnostic de maladies neurodegeneratives
JP2004530904A (ja) 蛋白質プロフィール化による腎臓病の検知方法
JPH04505865A (ja) アルツハイマー病診断測定法
US20060188951A1 (en) Method for measuring the level of anti-beta-amyloid antibody in body fluids and diagnostic kit for alzheimer's disease using same
US20080076140A1 (en) Biomarkers of Alzheimer's Disease
WO2010005387A1 (fr) Procédé et marqueurs inédits pour le diagnostic de la sclérose en plaques
US7105485B2 (en) HO-1 suppressor as a diagnostic and prognostic test for dementing diseases
US20210208165A1 (en) Protein biomarkers for nephropathy and applications thereof
WO2008031190A1 (fr) Alpha-1-antitrypsine comme indicateur de diagnostic/pronostic pour des maladies neuro-dégénératives
EP1371986A1 (fr) Diagnostic de la maladie d'Alzheimer basé sur le rapport entre hAbèta42 et hAbèta40
WO2002022165A9 (fr) Marqueurs proteiques pour maladies non genetiques
US8394639B2 (en) Biomarkers for renal disease
JP2023536162A (ja) 神経変性疾患の診断と予後推定におけるマーカーとしてのｐ５３の翻訳後修飾
ASSAY P1-365 A METHOD FOR MEASURING ANTI-BETA AMYLOID (Aß) OLIGOMER ANTIBODIES IN HUMAN PLASMA AND INTRAVENOUS IIMMUNOGLOBULIN

Legal Events

Date Code Title Description
FZDE Discontinued